Lucinaktant
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Respiratorno (inhalacija) |
| Identifikatori | |
| CAS broj | 825600-90-6  |
| ATC kod | R07AA30 (WHO) |
| DrugBank | DB04897 |
Lucinaktant je sintetički peptidni surfaktant za intratrahealnu primenu. Ovaj tečni lek se koristi za tretiranje respiratornog distresnog sindroma novorođenčeti. FDA je odobrila ovaj lek u martu 2012.[1]
Lucinaktant se sastoji od sinapultida, hidrofobnog, 21 aminokiselinu dugog peptida (ponavljajuće jedinice leucina i lizina, KL4 peptid), koji je dizajniran da oponaša ljudski surfaktantni protein-B (SB-P). Specifičnije, on oponaša C-terminal amfipatičnog heliksnog domena tog proteina. On takođe sadrži fosfolipide (dipalmitoilfosfatidilholin, DPPC i palmitoiloleoil fosfatidilglicerol, POPG) i masnu kiselinu (palmitinsku kiselinu).[2][3][4][5][6][7][8][9][10]
Reference
[уреди | уреди извор]- ^ „FDA approves Surfaxin to prevent breathing disorder in premature infants”. Fda.gov. 6. 3. 2012. Приступљено 20. 10. 2012.
- ^ Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. Sinha, S. K.; Lacaze-Masmonteil, T.; Valls i Soler, A.; Wiswell, T. E.; Gadzinowski, J.; Hajdu, J.; Bernstein, G.; Sanchez-Luna, M.; Segal, R.; Schaber, C. J.; Massaro, J.; d'Agostino, R.; Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group (април 2005). „A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome”. Pediatrics. 115 (4): 1030—8. PMID 15805381. doi:10.1542/peds.2004-2231.
- ^ Moya, F.; Sinha, S.; Gadzinowski, J.; d'Agostino, R.; Segal, R.; Guardia, C.; Mazela, J.; Liu, G.; SELECT and STAR Study Investigators (2007 June). „One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: Results from 2 multicenter randomized, controlled trials”. Pediatrics. 119 (6): e1361—70. PMID 17533176. doi:10.1542/peds.2006-0149. Проверите вредност парамет(а)ра за датум:
|date=(помоћ) - ^ Halliday HL, Speer CP: Lucinactant versus poractant-alpha in premature lambs. Halliday, H. L.; Speer, C. P. (јун 2006). „Lucinactant versus poractant-alpha in premature lambs”. Pediatrics. 117 (6): 2324—5. PMID 16740886. doi:10.1542/peds.2006-0469.; author reply 2325. PMID 16740886
- ^ Gastiasoro-Cuesta E, Alvarez-Diaz FJ, Rey-Santano C, Arnaiz-Renedo A, Loureiro-Gonzalez B, Valls-i-Soler A: Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Pediatrics. Gastiasoro-Cuesta, E.; Alvarez-Diaz, F. J.; Rey-Santano, C.; Arnaiz-Renedo, A.; Loureiro-Gonzalez, B.; Valls-i-Soler, A. (фебруар 2006). „Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome”. Pediatrics. 117 (2): 295—303. PMID 16452346. doi:10.1542/peds.2005-0378.
- ^ Donn SM: Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Donn, S. M. (март 2005). „Lucinactant: A novel synthetic surfactant for the treatment of respiratory distress syndrome”. Expert Opin Investig Drugs. 14 (3): 329—34. PMID 15833063. doi:10.1517/13543784.14.3.329.
- ^ Moen MD, Perry CM, Wellington K: Lucinactant: in neonatal respiratory distress syndrome. Moen, M. D.; Perry, C. M.; Wellington, K. (2005). „Lucinactant: In neonatal respiratory distress syndrome”. Treat Respir Med. 4 (2): 139—45. PMID 15813666. doi:10.2165/00151829-200504020-00008.; discussion 146-7. PMID 15813666
- ^ Doyle I: Lucinactant (Discovery Laboratories). IDrugs. Doyle, I. (јул 2002). „Lucinactant (Discovery Laboratories)”. Idrugs : The Investigational Drugs Journal. 5 (7): 696—702. PMID 12802703.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
